



**IMPACT & PROGRESS**

# REPORT 2024

Empowering entrepreneurs  
to crush cancer



Fondation  
Fournier-Majoie

## A WORD FROM THE PRESIDENT

Ladies and Gentlemen,  
Dear friends of the Foundation,

Every year, we see just how much expertise, commitment and generosity combine to advance cancer research.

**In 2024**, this dynamic was once again illustrated by the team around me: our committed employees, our **experienced consultants and the members of our Scientific and Administrative Boards**. **Thanks to their expertise, we are able to identify and support truly innovative projects, capable of transforming hope into reality for patients.**

The example of ATB Therapeutics' **Tobacco to treat cancer** project is particularly telling. From the outset, the Foundation believed in their innovative approach: using tobacco plants to produce 'missiles' capable of targeting tumor cells without affecting healthy cells. Thanks to the generosity of our donors, nearly **€1,300,000** has been allocated to ATB Therapeutics since the beginning of our commitment to this promising project, strengthening its credibility and attracting new investors. As a result, they have raised an exceptional **€54 million** to take a decisive step towards patients.

To support our projects, we organize an extraordinary **gala evening** every year, which continues to unite tremendous outpourings of solidarity. In 2024, our gala plunged guests into the world of *Harry Potter at the Researchers' School*, reminding them that true magic lies in generosity.



Sport is also proving to be a powerful mobilizing force. More and more supporters are running or walking the 20 km of Brussels in the Foundation's colors, while others are taking on individual sporting challenges in support of research. Mathilde, Sarina and Olivier, for example, walked the Camino de Compostela in aid of the Foundation, proving that everyone can make a difference in their own way.

We're already looking ahead to our 2025 focus project: **'Lighting the fire'**, supported by Hephaistos Pharma. Because so-called 'cold' tumors escape our immune system, the innovative therapy under development transforms them into 'hot' tumors, making them detectable and attackable by our immune cells. This approach opens up a new avenue, particularly for patients suffering from osteosarcoma, a particularly aggressive bone cancer affecting young people aged between 12 and 20. Eventually, this start-up will tackle other resistant cancers.

Your support is the driving force behind these advances. Every donation, every initiative, every helping hand contributes to building a future where cancer treatments are ever more effective and accessible. Thank you for being part of this human and scientific adventure, and for proving, year after year, that generosity can change lives.

With all my gratitude,  
Jérôme Majoie  
Chairman

A handwritten signature in black ink, appearing to read 'J. Majoie', with a long horizontal line extending to the right.



# OUR IMPACT MEASURED IN 2024

**7**

active projects

**596**

generous donors

**453K €**

raised to support scientific projects

## SINCE OUR CREATION

**161**

jobs created within the teams of our winners

**328**

projects analysed and commented

**20**

projects supported

**42**

patents filed

**+ 12M€**

**ALLOCATED TO RESEARCH PROJECTS**

## OUR MISSION :

To save lives, we identify, fund and support researchers so that their scientific discoveries benefit people suffering from cancer.



# CANCER, A GLOBAL SCOURGE



Around **50 million people** are (over)living with cancer worldwide today.

Behind these impressive figures are the children, men and women who suffer, whether directly affected by the disease or indirectly impacted as loved ones..



## 50 YEARS AGO,

only 1 in 4 patients survived cancer. Since then, research has led to a better understanding of the disease.

Treatments have diversified and improved considerably (surgery, chemotherapies, radiotherapies, immunotherapies, targeted therapies).

## TODAY,

with an overall survival rate of around **1 in 2**, cancer still claims more than 10 million direct victims worldwide every year.

1 in 2 is better, but far from enough. **There are still so many lives to be saved!**

**Supporting research is today our only option for improving existing therapeutic solutions and developing new diagnostics and treatments.**

## OUR HISTORY

At the age of 27, **Bernard Majoie**, doctor of pharmacy, seized the opportunity to develop a pharmaceutical R&D department within Laboratoires Fournier. He propelled this 400-strong family business into a global laboratory employing over 4,000 people.

Building on this success and driven by a desire to **return the favour**, he created the Fournier-Majoie Foundation in 2007.

His aim: **to help researchers become entrepreneurs** against cancer, so that their scientific discoveries can help beating cancer. Indeed, in the course of his entrepreneurial career, Bernard Majoie has come to realize that many promising cancer research projects fail to reach patients, due to a lack of adequate financial and managerial support.

On the occasion of the Foundation's 10th anniversary in 2017, Bernard Majoie passed the baton to his son **Jérôme**. Bernard Majoie passed away in December 2021, leaving his philanthropic mark on the Foundation with the many hopeful projects it supports.



*Bernard  
Majoie*



*Jérôme  
Majoie*




# OUR MOMENT OF INTERVENTION

It all begins in a **laboratory** where a researcher and his/her team make a promising discovery. A **patent** is then filed and hypotheses are established to transform/improve this discovery into a therapeutic solution.

Next, they have to provide **proof of concept** that will demonstrate: how it acts in the body, its efficacy and tolerability, while detailing how it can be produced on a large scale and in a stable manner.

## THE FOUNDATION HELPS RESEARCHERS AT A CRUCIAL MOMENT

It is at this key moment, just after proof of concept, that the Fournier-Majoie Foundation has chosen to intervene. It provides **financial resources AND entrepreneurial support** to researchers to encourage the success of the pre-clinical phases and prepare for the project's entry into the clinical phases (those involving the first patients). We then hand over to other players, whether investors or industrialists, with a partly deris- ked project that has real medical perspectives.





# THE FOUNDATION'S TRIPLE SUPPORT

It is not always easy for the researcher to put on the suit of an entrepreneur and find funding to support his/her project. They have to face a real obstacle course until the therapeutic solution can actually be made available to patients.

To increase the project's chances of success, the Foundation carries out a rigorous analysis of promising oncology projects that could bring tangible medical advances to various cancers: ovarian cancer, colorectal cancer, breast cancer, kidney cancer, stomach cancer, blood cancer, bone cancer and many others.

The Foundation's rigorous analysis of projects is based on 14 scientific, commercial and financial criteria

Once selected, the Foundation supports its laureates in

## 3 WAYS

1

**Financial resources** (up to €2.5 million per project) at a stage of development when investors are generally reluctant to invest

2

Real **entrepreneurial support** by involving a vast network of scientific, technical, financial and business experts

3

Access to a **network of private and public investors** in the context of fundraising

# WHY IS THE FOUNDATION UNIQUE ?

1.




## ENTREPRENEURIAL PHILANTHROPY AND PHILANTHROPRENEURS

**This hybrid concept linking philanthropy and entrepreneurship perfectly defines the DNA of the Fournier-Majoie Foundation.**

**Philanthropy** because we combine altruism, absence of personal enrichment and commitment.  
**Entrepreneurial** because our support consists precisely in empowering and advising the project leader in his or her entrepreneurial process, while limiting the risks as much as possible through impact assessments and in-depth evaluation of the projects' potential.  
**'Philanthropreneurs'** are the figurehead of this new approach to philanthropy based on efficiency and impact, borrowed from the business world.

2.



## 100% MODEL: FOR MAXIMUM IMPACT OF YOUR GENEROSITY

**The full amount of your donations is directly and exclusively allocated to oncology research projects: this is our commitment.**

All the operating costs of the Foundation are covered by a separate endowment from our founder, Bernard Majoie.  
Your donations are tax-deductible in most European countries and in the United States.




# 3.

## OUR DNA IS CLOSE TO THAT OF ENTREPRENEURS

Our entrepreneurial spirit is clearly reflected in our vision "Empowering entrepreneurs to crush cancer", and in a series of characteristics that business leaders will immediately identify with:

1. A strong **ambition** aiming to provide new therapeutic solutions
2. (Measured) **risk-taking** by committing our capital after a rigorous selection of projects
3. A search for **impact** by helping to save lives and creating jobs (👉 jobs created within the teams of our laureates)



# 4.

## VIRTUOUS CIRCLE

Aware of the opportunities he had been offered to become an entrepreneur and to open the doors to success, our founder, Bernard Majoie, was keen to "**return the favour**". This philosophy remains one of the driving forces behind our action today.

Indeed, each laureate who benefits from the Foundation's support undertakes to help future researchers if their initiative is successful.

**From being helped, they thus become helpers** and contribute to the formation of a virtuous circle that characterises the Foundation. The donations we receive become **permanent**: they support not one but several successive projects.



### A concrete example of the virtuous circle: MABLINK Bioscience

Our 'invisibility cloak' project, led by MABLINK Bioscience, continues to demonstrate the impact of innovation in oncology.

After being acquired by Eli Lilly thanks to the advances of its hydrophilic cloak (PSARlink), Mablinc has reached a decisive milestone: its targeted therapy has now been administered to the first 30 patients, offering them a new perspective in the fight against the disease. This success illustrates the power of supporting research. The return on mission will be used to support promising new cancer projects.

# OUR MAJOR IMPACTS



## HEALTH IMPACT

---

- Saving lives
- Develop new cancer treatments
- Improve the quality of life of patients



## 8X IMPACT

---

**€1 put on the table generates  
€8 in reality**

Thanks to the combination of:

- tax deductibility
- public funds
- other private funding federated through the Foundation's reputation



## ECONOMIC IMPACT

---

- 161 jobs created
- Helping researchers become entrepreneurs
- Supporting scientific innovation



## SUSTAINABLE IMPACT

---

- A virtuous circle as a driving force
- If the project is successful, the laureates commit to helping future researchers
- Your donation supports not only one but several successive projects

The butterfly effect is at the heart of our action and symbolises the powerful idea that each small gesture, each small act of solidarity, combined with others, can have **extraordinary consequences** for those who are courageously fighting the disease.

If all the projects supported by the Foundation today were to succeed, they could have a vital impact on

**7,2 millions de personnes.**

Each project supported is a ray of hope for patients waiting for treatment for their cancer. Just as every donation represents another step towards a future without cancer.

## THE BUTTERFLY EFFECT TO SAVE LIVES



# OUR PROMISING CANCER PROJECTS



PROF. TONY LAHOUTTE

**LAMA DE TROIE**  
**PRECIRIX**

**TARGETED CANCERS :**  
**HER2+ BREAST CANCER WITH**  
**BRAIN METASTASES**

Precirix develops and manufactures precision radiopharmaceuticals based on llama-derived antibodies that deliver radioactive isotopes to cancer cells overexpressing HER2 receptors in a highly targeted manner. These include certain **breast and stomach cancers**.

Llama nano-antibodies are 10 times smaller than conventional antibodies (1 million nano-antibodies can be placed on a 1 mm surface!), enabling them to circulate very rapidly in the body, bind to receptors that are difficult to detect due to their size, and carry small radioactive charges that are powerful enough to destroy cancer cells.

Another substantial advantage linked to size is their ability to reach cancer cells that have arrived in the brain to develop. It should be borne in mind that the vast majority of therapeutic molecules do not pass through the natural blood-brain barrier that protects the brain from undesirable substances circulating in the blood. Precirix nano-antibodies, on the other hand, are able to target these cells.

New research is underway to explore promising therapeutic targets.

DNALytics is a spin-off from the Université Catholique of Louvain. Its expertise lies in the statistical analysis and validation of research data and the formulation of recommendations for the development and marketing of products and services in the healthcare sector.

Since 2021, the company has refocused its activities around the distribution of BRICKS, a range of bioinformatics software used in R&D.

It has also updated its HERCULE platform for consolidating and validating production data for major biopharmaceutical companies.



DOCTOR THIBAUT HELLEPUTTE







DR. BERTRAND MAGY



# PRIORITY 2024 PROJECT

## TOBACCO TO TREAT CANCER

**TARGETED CANCERS:**  
**NON-HODGKINIAN LYMPHOMA**  
Then potentially solid tumors

Building on its promising advances, ATB Therapeutics has successfully raised €54 million in 2024 to accelerate the development of innovative treatments for cancer and autoimmune diseases. The funding will be used to enhance its ATBioFarm platform and create breakthrough therapeutic antibodies. Research activities will be expanded in Ghent, with a new pilot manufacturing facility under-way in Marche-en-Famenne.

**THANKS TO THE GENEROSITY OF OUR DONORS, WE HAVE RAISED €453,000 IN 2024 TO BRING THIS PROJECT CLOSER TO THE CLINICAL PHASE, FOR THE BENEFIT OF THE FIRST PATIENTS.**

### ***Would you have imagined that tobacco could one day cure cancer?***

That's what Dr Bertrand Magy, Max Houry and their team, based near Marche-en-Famenne (B), are about to demonstrate thanks to our support. They have designed a new class of drugs to combat blood cancer and certain solid cancers, based on tobacco plant derivatives: they are named atbodies (antibody-toxin-bioengineered).

One of the special features of atbodies is that they form an all-in-one anti-cancer missile, combining a homing device to target cancer cells and a toxin to destroy them. This therapy in development is proving to be extremely powerful against cancer cells (the toxins are highly concentrated), highly targeted (particularly for blood cancers) and 2 x faster to manufacture than traditional targeted therapies.



JEAN-GUILLAUME LAFAY, CEO AND CO-FOUNDER OF MABLINC BIOSCIENCE WITH DR WARREN VIRICEL

### THE CLOAK OF INVISIBILITY



In targeted therapy, "missiles" (known as Antibody Drug Conjugates or ADCs) with a homing head, a linker and a payload of toxic agents are injected intravenously to flush out cancer cells. They attach themselves to their target on the surface of the cancer cells and destroy them, while leaving healthy tissue unharmed. The problem is that these missiles and their toxic cargo are transported by the bloodstream and pass through the liver, which risks filtering and eliminating them, thus reducing the strike force and causing unwanted liver poisoning.

With its own technological platform, our laureate has designed a "cloak of invisibility" that envelops the cytotoxic payload and makes it invisible to the liver's filtering cells. Consequently, the missile equipped with the cloak of invisibility reaches its target with full power. This patented hydrophilic cloak is called PSARlink.

The efficacy/tolerability ratio has been measured to be 7 to 10 times higher than currently available targeted therapies.

At the end of 2023, MABLINC was acquired, enabling the Foundation to support new promising cancer projects thanks to the financial return on the Invisibility Cape.

**In 2024, this targeted therapy was administered to the first 30 patients, offering them a new perspective against their illness.**

### TARGETED CANCERS: LUNG, BREAST, OVARIAN, COLORECTAL

### TARGETED CANCERS: OVARIAN AND COLORECTAL

Cancer's first enemy is our immune system, whose mission is to destroy abnormally functioning cells. But underhandedly, cancer develops defensive strategies. In certain cancers, cells have the particularity of producing a protein (called TSP-1) which forms a cloud-like mass around the cancer cell, rendering our immune system inoperative. Colorectal and ovarian cancer often use this defensive tactic.

At Apmonia Therapeutics, **Dr. Albin Jeanne and his team** have developed TAX2, a highly promising immunotherapy treatment that targets the protein TSP-1 to "**chase the clouds**", enabling our immune system to spot cancer cells and fight them.

In 2024, TAX2 development also moved into advanced solid tumors, oncology target analysis technology improved and the treatment portfolio expanded with new scientific evidence. In terms of financing, the company has benefited from significant support of just over 12 million euros (France 2030 and EIC Accelerator).



DR. ALBIN JEANNE, SCIENTIFIC RESEARCHER AND MANAGER, CO-FOUNDER OF APMONIA THERAPEUTICS

### CHASING THE CLOUDS






FRÉDÉRIC CAROFF



**TARGETED CANCERS:  
OSTEOSARCOMA, LYMPHOMA,  
COLORECTAL CANCER AND  
PANCREATIC CANCER**

# FOCUS 2025 PROJECT

## LIGHTING THE FIRE



The Foundation is supporting the development of an immune system stimulant which is showing very promising cure rates, particularly for cancers for which there is currently no convincing treatment.

To enable the immune system to better detect and eliminate hidden tumors, **ONCO-Boost** transforms 'cold' tumors into 'hot' ones. This innovative therapy makes them visible to immune cells, which can then attack and destroy them.

Initially, the aim is to develop this product as a monotherapy against **osteosarcoma**, a highly aggressive bone cancer affecting 12-20 year-olds in particular.

It will then be combined with existing immunotherapies that are ineffective against other cancers, to restore their natural efficacy.

### Advantages over existing molecules:

The ONCO-Boost molecule is soluble and has low toxicity, enabling it to be administered intravenously. With an optimized toxicity profile, it also offers a better therapeutic index (minimum effective dose without adverse effects).

### Major project advances in 2024

- Positive preclinical results in pancreatic cancer (in addition to lymphomas, osteosarcoma and colorectal cancer)
- Positive results in combination with chemotherapies
- Start of industrial transfer of production

**WITH YOUR HELP, WE AIM TO RAISE 500,000 EUROS BY 2025  
TO SUPPORT THIS PROJECT, WHICH BRINGS HOPE TO  
THOUSANDS OF PATIENTS.**

### In concrete terms, how will your generosity be used?

To bring the molecule into clinical trials, the Onco-boost solution will have to be produced to very high-quality standards. In total, the production budget is expected to exceed €3 million.

In addition to the development and production of the treatments, an amount of €35,000 per patient is to be considered to cover hospital costs during the initial clinical phases. The aim is to be able to inject the treatment into the first patients in 2027.



# GOVERNANCE AND TEAMS

## BOARD OF DIRECTORS

**Committed people mobilised to achieve our mission**

Since 2017, our Foundation is chaired by **Jérôme Majoie**. The Board of Directors is composed of six members. All of them work *pro bono*.

**Jérôme Majoie**,  
Chairman and CEO of the Fournier-Majoie Foundation  
**François Charlet**,  
Managing Partner of Intuitae Switzerland  
**Rudy Dekeyser**,  
Associated Director of LSP Health Economics Funds  
**Frédéric Galland**,  
Financial and Administrative Director of the Fournier-Majoie Foundation  
**Jacques Mallet**,  
President and CEO of Gamma-X Corporate Advisory  
**Paul Van Dun**,  
General Manager of the KU Leuven Research and Development Department

# SCIENTIFIC AND INVESTMENT

## ADVISORY BOARD

In order to achieve its mission, the Foundation also relies on a Scientific and Investment Advisory Board, which auditions project leaders in order to evaluate, first of all, the durability and relevance of the scientific innovation.

This multi-disciplinary council is made up of experts in oncology and biostatistics, industrial practitioners in the field of clinical development and investment-fund managers. It ensures that the selected projects satisfy the scientific, commercial and financial criteria and are likely to result in innovative and effective solutions to current oncological issues.

**All of these experts contribute to the assessment and monitoring of projects on a pro bono basis.**

Professor Jean-Pierre Armand  
Doctor Vincent Brichard  
Professor Marc Buyse  
Doctor Rudy Dekeyser  
Professor Ferdinand Lejeune

Doctor Jacques Mallet  
Professor Bart Neyns  
Mister Jan Pensaert  
Mister Paul Van Dun



## THE OPERATIONS TEAM

The Foundation is actively managed on a day-to-day basis by a team comprising **Jérôme Majoie** (Chairman and CEO), **Frédéric Galland** (Finance and Administration), **Mathilde Jooris** (Philanthropy), **Coralie Lion** (Communication) and **Serge Schmitz** (Fundraising Strategy and Communication).

Jérôme Majoie can also count on the expertise of **Ana Maricevic** for competitive analyses and **Dr Peter De Waele** for scientific aspects and intellectual property.



## THE HONORARY COMMITTEE

### 2024

The role of our **Ambassadors** is to spread the name and mission of the Foundation. They are particularly active in the preparation of the Gala evening, in particular through their ideas, advice, multiple contacts and search for tombola prizes. All of them carry out their mission on a voluntary basis.

Daniel Abelew  
Jean-Cédric van der Belen  
Sarina de Ganay  
Gwenaële de Meulemeester  
Vinciane Morel de Westgaver

Caroline de Strycker  
Stéphane d'Udekem d'Acoz  
Sébastien Ulens  
Virginie Vaxelaire

# OUR EVENTS IN 2024


SUPPORTING THE FOURNIER-MAJOIE FOUNDATION THROUGH ITS EVENTS  
MEANS WORKING TOGETHER TO COMBAT THE GLOBAL SCOURGE OF CANCER.



## 20 KM OF BRUSSELS

MAY 2024

"THE" legendary event for thousands of athletes in the capital. Thanks to all our heroes who took up the challenge, proudly wearing the colors of the Fournier-Majoie Foundation and to all those who supported them with their donations!

The various events organized in 2024 raised  
no less than  **453.000.**

## GALA EVENING « HARRY POTTER »

SEPTEMBER 2024

Every year, the Fournier-Majoie Foundation organizes a prestigious dinner followed by an evening of dancing at an exceptional venue. In 2024, the Gala evening plunged our guests into the magical world of *Harry Potter at the Researchers' School*.

Our Wizards and Witches proved that the magic lies in their generosity and commitment to advancing cancer research.



## TENNIS TOURNAMENT

SEPTEMBER 2024

The Tennis Club Uccle Churchill turned sport into a driving force for solidarity by organizing a tournament in aid of cancer research. Combining commitment, generosity and team spirit, the event was a fine demonstration of support and hope, supported by the enthusiasm of the participants and the warm welcome extended by the club.



## LES VOILES DU ZOUTE SEPTEMBER 2024

For the 3rd year running, the Foundation was the charity partner of the inter-company regatta "Les Voiles du Zoute", which took place in the famous seaside resort of Knokke-Heist. This regatta is a unique opportunity to combine sporting competition, networking and generosity in aid of cancer research. After the competition, participants gathered for dinner and the auction of a magnificent work of art created live by the painter-performer Réналd Zapata.

## "IT'S MAJOIE TO INVITE YOU" DINNERS

The idea behind these solidarity dinners is to ask guests to come empty-handed (no wine, flowers, chocolates, etc.) and instead make a donation to fight cancer in a different way. The aim is for one of the guests to take over, creating a chain of dinners in aid of the Foundation.



## SPORTING CHALLENGES

Whether solo, with family, friends or colleagues, the aim of these sporting challenges is to set yourself a challenge while mobilizing those around you to support cancer research.

Thank you to Sarina, Mathilde and Olivier, who took to the roads of Compostela to help us save lives.

# HOW CAN YOU SUPPORT US?

**Anne-Sophie Eymeoud**  
**Rothschild & Co Wealth Management**  
(Family bank with a historical philanthropic DNA)

*"From the moment I met Bernard Majoie, whom I consider to be one of the pioneers of entrepreneurial philanthropy in Europe, I was enthusiastic about his project, which is at the crossroads between entrepreneurship, philanthropy and impact. It enables start-ups to grow and to raise the profile of European medical research."*

## Thanks to our partners:

ADC Production, Artfood Traiteur, Bility, Buy Way, Chant d'Eole, Doktor Jack, Gillion, Gueuleton, Intesa Sanpaolo Wealth Management, Julius Bär, Leonidas, Leopold Café Presse, Le Yokan Lodge, Maison Eole, Maison Hädenn, Manoir Nestor, Nagelmackers, Porsche Louvain-La-Neuve, Rouge Pivoine, Rothschild & Co Wealth Management, Smart Games, So Excentrique, Voiles du Zoute, WMH Project.



## CORPORATE PARTNER

As a company, you have the opportunity to help save lives by supporting scientific research. Benefit from positive spin-offs by getting involved in a philanthropic and entrepreneurial approach tackling a major social issue.

**Join us in "Empowering entrepreneurs to crush cancer" and become a corporate partner of the Fournier-Majoie Foundation:**

- by inviting your staff to get involved and support the cause and the Foundation
- by donating part of the sale of your products/services to the Foundation
- by offering products or services
- by sponsoring our events

**Contact us:**

**[philanthropreneur@fournier-majoie.org](mailto:philanthropreneur@fournier-majoie.org)**

**Tel : +32 2 370 47 23**



# OTHER WAYS TO HELP US

By supporting our promising scientific projects, you are bringing a breath of hope to those suffering from cancer.

**Your generosity can be fiscally attractive and have a human impact.**



## DONATE

- Make a tax-deductible donation
- Include the Foundation in your will
- Shop online with Trooper ([www.trooper.be](http://www.trooper.be))



## COLLECT

- Organize a solidarity dinner
- Create your own Challenge 2024
- Celebrate a personal event (birthday, wedding, birth, etc.)
- Honor the memory of a loved one



## PARTICIPATE

- Run or walk the 20 km of Brussels
- Join us for our Gala evening

# THANK YOU!

**Thank you from the bottom  
of our heart for your generosity!**

- To our Donors
- To our Honorary Committee
- To our Partners and Companies who actively supported us in 2024
- To the artists and personalities who support our cause: Billie Behagel de Bueren, Gérald de Patoul, Olivia de Posson, Edouard Gillès, Stéphanie Haegelsteen, Darko Justa, Gabriel Lelièvre, Bertrand Piccard, Antoine Rose, Stéphanie Van Beneden, Jules Wittock, Réналd Zapata

## MAKE A DONATION

**You too can become a Philanthropreneur  
by supporting cancer research**

### IF YOU ARE A BELGIAN RESIDENT

By making a minimum donation of 40 EUR over the calendar year, you can benefit from tax advantages.

Bank account: King Baudouin Foundation / FFM

IBAN: BE10 0000 0000 0404

BIC: BPOTBEB1

Communication: +++197/0370/00076+++ (important to mention)

### IF YOU ARE NOT A BELGIAN RESIDENT OR DO NOT REQUEST A TAX CERTIFICATE

You can donate to us directly

Bank account: Fournier-Majoie Foundation

IBAN: BE43 0689 4204 2001

BIC: GKCCBEBB

Communication: Impact report

SCAN TO MAKE  
A DONATION



[www.fournier-majoie.org](http://www.fournier-majoie.org)

Avenue de Fré 269 / bte 44 – 1180 Brussels – Belgium

Email : philanthropreneur@fournier-majoie.org – Phone number : +32 2 370 47 25

Follow all our news on social media

